Clinical trials
A Clinical Trial is a research study that is performed on patients to test the efficiency and safety of a drug. Their results are fundamental to advance in the treatment against cancer. Its development is based on the search for new therapies, which are more effective and less toxic than conventional therapies.
Within the Oncoavanze group we have Phase II and III Clinical Trials in different pathologies, which are at the service of all our potential candidate patients.
PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.AFT-38.
Status: Open
FLIPPER: A Randomized, Double-blind, Parallel-group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FaslodexTM) 500mg With Placebo and Fulvestrant (FaslodexTM) 500mg in Combination With PD-0332991 (Palbociclib) as First Line Treatment for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer, Who Have Completed at Least 5 Years of Adjuvant Endocrine Therapy and Remained Disease Free for More Than 12 Months Following Its Completion or Have “de Novo” Metastatic Disease. “The FLIPPER Study”.GEICAM/2014-12.
Status: Open
NATALEE: A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone recpetor-positive, HER2-negative, early breast cáncer (New Adjuvant TriAL with Ribociclib [LEE011]: NATALEE).
Status: Open
PALLAS: PALbociclibCoLlaborative Adjuvant Study:A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) /human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.AFT-05/ ABCSG-42/ BIG-03.
Status: Finished
POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer). Código estudio: IBCSG 48-14 / BIG 8-13 POSITIVE. Promotor: Grupo internacional para el estudio del cáncer de mama (IBCSG).
Status: Finished
EUFORIA-1: Retrospective, observational analysis of the use of Eribulin (Halaven) in the treatment of advanced breast cancer (locally recurrent or advanced.
Promotor: EISAI Farmacéutica, S.A
ZARAS STUDY: Retrospective study of clinical practice with Zometa® (zoledronic acid) in patients with metastatic breast cancer in Spain. ZARAS: Zoledronic, AcidRetrospectiveAudit in Spain.
Promoter: NovartisFarmaceútica S.A.
HERMEX: Multicenter, observational, cross-sectional, descriptive study to understand the treatment schemes with Xeloda ® (Capecitabine) in monotherapy or as part of a combined chemotherapeutic regimen and the clinical profile of HER2 + and HER2- patients with metastatic breast cancer within of the usual clinical practice.
Promoter: Burgos Foundation for Health Research.
TAX-FEC-POSITIVE: Phase II study with docetaxel followed by the combination Fluoracilo + epirubicin + cyclophosphamide as adjuvant treatment of breast cancer in the initial stage, operated and with axillary involvement.
Promoter: ONCAMI research group (Oncologists Associate Researchers).
TAX-FEC NEGATIVE: Phase II study with docetaxel followed by the combination fluoracilo + epirubicin + cyclophosphamide as adjuvant treatment of breast cancer in the initial state, operated and without axillary involvement.
Promoter: ONCAMI research group (Oncologists Associate Researchers).
CHA-IIAA-2004-01: Multicenter study of the prevalence of COX-2 mRNA in peripheral blood in patients with metastatic breast cancer (MBC).
Promoter: Reina Sofía Hospital, Córdoba.
ARO-IIG-9: Study to evaluate the effectiveness of the hormonal treatment according to the molecular subtypes (lumin A and B), in patients with metastatic breast cancer.
Promoter: Virgen del Rocío Hospital, Seville
MM 0108: Multicenter sequential care study for patients with metastatic breast carcinoma in first line treatment with Myocet followed by Taxotere and subsequent stratification according to tumor biology.
Promoter: ONCAMI research group (Oncologists Associate Researchers).
TAXCET: Multicenter study with the combination of biweekly Myocet and Docetaxel as a neoadjuvant treatment of patients with locally advanced breast cancer.
Promoter: ONCAMI research group (Oncologists Associate Researchers)
TEC-ABC PROTOCOL: Multicenter pilot study of adjuvant treatment with Taxotere, Epirubicin and Cyclophosphamide (TEC), in patients with stage II and III breast carcinoma and positive axillary lymph nodes.
Promoter: ONCAMI research group (Oncologists Associate Researchers)
AST-ANA 2004-01 STUDY: Study of endometrial changes in postmenopausal patients with breast cancer under adjuvant treatment with ANASTROZOL
Promoter: AstraZenecaFarmaceúticaSpain. S.A
BCIRG 006: Multicenter phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) and with docetaxel, carboplatin and trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER2neu alteration
Promoter: Aventis Pharma S.A
Cooperative Group: Spanish Breast Cancer Research Group (GEICAM).
GO40290: A phase II, randomized, blinded, placebo-controlled study of MTIG7192A, an anti-TIGIT antibody, in combination with atezolizumab in chemotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer.GO40290.
Status: Open
JAVELIN: A phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinun-based doublet as a first line treatment of recurrent or Stage IV PD-L1+ non-small-cell lung cáncer.EMR 100070-005.
Status: Finished
TARGET clinical trial ML17915: open-label, nonrandomized phase II study to assess the efficacy and safety of Tarceva (erlotinib) monotherapy in patients with advanced non-small cell lung carcinoma (CNMP).
Promoter: Roche Farma, S.A.
Status: Finished
NEOTAX H&N STUDY: Phase II study of neoadjuvant chemotherapy (Docetaxel / Cisplatin / 5-FU) followed by concomitant radical radiotherapy with cisplatin in locally advanced head and neck cancer.
Promoter: ONCAMI research group (Oncologists Associate Researchers).
Status: Finished
PETAAC-8 CLINICAL TRIAL: Adjuvant treatment of fully resected stage III colon cancer with FOLFOX-4 plus Cetuximab vs FOLFOX-4.
Promoter: FédérationFrancophone de CancérologieDiegestive Faculté de Médecine.
Cooperative Group: Spanish Group for the Treatment of Digestive Tumors (TTD)
Status: Finished
AVATRAN STUDY: Multicenter, cross-sectional observational study to describe the clinical profile of patients with metastatic colon or rectum carcinoma treated with avastin in the first line treatment.
Promoter: Roche Farma, S.A.
Status: Finished
TTD-OXA-2003-01: Prospective study to evaluate the efficacy of oxaliplatin + 5FU administered every two weeks in patients older than 72 years with advanced colorectal cancer.
Promoter: Spanish Group for the Treatment of Digestive Tumors (TTD).
Status: Finished
O3-TTD-01: Multicenter, randomized and open-label, phase III study to compare the efficacy and safety profile of the combination of capecitabine and oxaliplatin versus the combination of 5-Fluorouracil in continuous infusion and oxaliplatin as a first-line treatment in metastatic or advanced colorectal cancer.
Promoter: Spanish Group for the Treatment of Digestive Tumors (TTD).
Status: Finished
XEGATRAN: Cross-sectional observational study to establish the relationship of functional status and age with the administration of doublet or triplet chemotherapy regimen containing Xeloda® (Capecitabine) in patients with advanced gastric carcinoma.
Promoter: Roche Farma S.A.
Status: Finished
SOG-PLA: Prospective study of the usefulness of liquid biopsy as a predictor and prognostic factor in patients with metastatic urothelial carcinoma progression after platinum-based chemotherapy. Abbreviated title: Usefulness of liquid biopsy in urothelial metastatic carcinoma in progression after platinum-based chemotherapy Protocol number: SOG-PLA-2016-01. PROMOTER: SOGUG (Spanish Genitourinary Oncologic Group).
Status: Open
PROMASIN: Evaluation of the efficacy and toxicity of sequential treatment with docetaxel in asymptomatic metastatic prostate carcinoma.
Promoter: ONCAMI research group (Oncologists Associate Researchers)
Status: Finished
Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD). NCT 03294746.
Status: Open
PRENEUF STUDY: Study of the efficacy of lenogastrin in the prevention and treatment of neutropenia.
Promoter: ONCAMI research group (Oncologists Associate Researchers)
Status: Finished